Compare DexCom, Inc. (DXCM) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Under Armour Inc Class A — how do they compare? DexCom, Inc. trades at $90.34 (market cap $33.79B), while Under Armour Inc Class A trades at $5.26 (market cap $2.26B). The key difference: DexCom, Inc. is far larger — about 15× Under Armour Inc Class A's market cap, and DexCom, Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| DXCM | UAA | |
|---|---|---|
Market Cap | $33.79B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $8.14 |
52-Week Low | $54.84 | $4.17 |
Enterprise Value | $33.24B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Under Armour (UAA) is trading at $5.265, down 10.15% with bearish technical signals despite recent earnings beats. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.7B in 2024 to $5.2B in 2025. Recent Q1 2027 earnings showed a profit beat but weaker revenue and cautious guidance, reflecting ongoing struggles in North American and Asia-Pacific markets. Cash flow remains negative at -$362M for 2025, though valuation ratios like P/S of 0.46 appear attractive relative to peers.
The outlook remains challenging with persistent revenue declines and profitability issues offset by potential value opportunities. Key risks include weak consumer spending, inventory management challenges, and competitive pressures. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels, though institutional sentiment appears cautious given the technical bearish signals and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
